Vinflunine - Pierre Fabre

Drug Profile

Vinflunine - Pierre Fabre

Alternative Names: F-12158; Javlor; L-0070; Vinflunine ditartrate

Latest Information Update: 18 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pierre Fabre
  • Class Antineoplastics; Vinca alkaloids
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bladder cancer
  • Preregistration Breast cancer
  • Phase III Head and neck cancer; Urogenital cancer
  • No development reported Mesothelioma; Non-small cell lung cancer; Solid tumours
  • Discontinued Gastric cancer; Ovarian cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jul 2017 Pierre Fabre completes a phase III trial in Breast cancer (Combination therapy, Locally recurrent, Metastatic disease, Second-line therapy or greater, Late-stage disease) in Taiwan, China, Singapore (IV) (NCT01953003)
  • 25 Jul 2016 Vinflunine licensed to Grupo Biotoscana in Colombia, Chile, Ecuador and Peru
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top